284 related articles for article (PubMed ID: 32076754)
1. [Gene-specific treatment approaches in muscle diseases].
Lehmann Urban D; Schneider I
Nervenarzt; 2020 Apr; 91(4):318-323. PubMed ID: 32076754
[TBL] [Abstract][Full Text] [Related]
2. [Antisense therapies for neurological diseases].
Pulst SM
Nervenarzt; 2019 Aug; 90(8):781-786. PubMed ID: 31165208
[TBL] [Abstract][Full Text] [Related]
3. Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle.
Vita G; Vita GL; Musumeci O; Rodolico C; Messina S
Neurol Sci; 2019 Apr; 40(4):671-681. PubMed ID: 30805745
[TBL] [Abstract][Full Text] [Related]
4. [Innovative therapeutic approaches for hereditary neuromuscular diseases].
Kirschner J; Schoser B
Nervenarzt; 2018 Oct; 89(10):1115-1122. PubMed ID: 30171303
[TBL] [Abstract][Full Text] [Related]
5. New developments in exon skipping and splice modulation therapies for neuromuscular diseases.
Touznik A; Lee JJ; Yokota T
Expert Opin Biol Ther; 2014 Jun; 14(6):809-19. PubMed ID: 24620745
[TBL] [Abstract][Full Text] [Related]
6. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
[TBL] [Abstract][Full Text] [Related]
7. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
8. Targeting RNA to treat neuromuscular disease.
Muntoni F; Wood MJ
Nat Rev Drug Discov; 2011 Aug; 10(8):621-37. PubMed ID: 21804598
[TBL] [Abstract][Full Text] [Related]
9. Precision Medicine through Antisense Oligonucleotide-Mediated Exon Skipping.
Li D; Mastaglia FL; Fletcher S; Wilton SD
Trends Pharmacol Sci; 2018 Nov; 39(11):982-994. PubMed ID: 30282590
[TBL] [Abstract][Full Text] [Related]
10. Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy.
Abreu NJ; Waldrop MA
Pediatr Pulmonol; 2021 Apr; 56(4):710-720. PubMed ID: 32886442
[TBL] [Abstract][Full Text] [Related]
11. A Half-Century History of Applications of Antisense Oligonucleotides in Medicine, Agriculture and Forestry: We Should Continue the Journey.
Oberemok VV; Laikova KV; Repetskaya AI; Kenyo IM; Gorlov MV; Kasich IN; Krasnodubets AM; Gal'chinsky NV; Fomochkina II; Zaitsev AS; Bekirova VV; Seidosmanova EE; Dydik KI; Meshcheryakova AO; Nazarov SA; Smagliy NN; Chelengerova EL; Kulanova AA; Deri K; Subbotkin MV; Useinov RZ; Shumskykh MN; Kubyshkin AV
Molecules; 2018 May; 23(6):. PubMed ID: 29844255
[TBL] [Abstract][Full Text] [Related]
12. Translational development of splice-modifying antisense oligomers.
Fletcher S; Bellgard MI; Price L; Akkari AP; Wilton SD
Expert Opin Biol Ther; 2017 Jan; 17(1):15-30. PubMed ID: 27805416
[TBL] [Abstract][Full Text] [Related]
13. Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies.
Chamakioti M; Karantzelis N; Taraviras S
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563214
[TBL] [Abstract][Full Text] [Related]
14. Better living through peptide-conjugated chemistry: next-generation antisense oligonucleotides.
McNally EM; Leverson BD
J Clin Invest; 2019 Nov; 129(11):4570-4571. PubMed ID: 31566581
[TBL] [Abstract][Full Text] [Related]
15. Recent advancements in exon-skipping therapies using antisense oligonucleotides and genome editing for the treatment of various muscular dystrophies.
Hwang J; Yokota T
Expert Rev Mol Med; 2019 Oct; 21():e5. PubMed ID: 31576784
[TBL] [Abstract][Full Text] [Related]
16. Gene Therapy for Hemophilia and Duchenne Muscular Dystrophy in China.
Liu X; Liu M; Wu L; Liang D
Hum Gene Ther; 2018 Feb; 29(2):146-150. PubMed ID: 29366352
[TBL] [Abstract][Full Text] [Related]
17. COST Actions: fostering collaborative research for rare diseases.
Desviat LR; Mallebrera CJ; Vallejo-Illarramendi A; Mayán MD; Nogales-Gadea G; Arechavala-Gomeza V
Lancet Neurol; 2019 Nov; 18(11):989-991. PubMed ID: 31609208
[No Abstract] [Full Text] [Related]
18. FDA-Approved Oligonucleotide Therapies in 2017.
Stein CA; Castanotto D
Mol Ther; 2017 May; 25(5):1069-1075. PubMed ID: 28366767
[TBL] [Abstract][Full Text] [Related]
19. [New treatments for spinal muscular atrophy].
Wurster CD; Günther R
Nervenarzt; 2020 Apr; 91(4):294-302. PubMed ID: 32076758
[TBL] [Abstract][Full Text] [Related]
20. Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets.
Barresi V; Musmeci C; Rinaldi A; Condorelli DF
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
